NEW YORK (GenomeWeb) – Chinese personalized oncology firm Burning Rock Biotech announced last week that it has closed a CNY150 million ($23.4 million) Series A+ financing round led by Jifeng Capital, Sequioa Capital, and Legend Star.

The firm said in a statement that it would use the proceeds to fund research and development. Burning Rock offers next-generation sequencing-based cancer diagnostics and personalized treatment plants based on genetic testing.

Burning Rock received CNY62 million in Series A financing in 2014 from Northern Light Venture Capital and Legend Star.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Jackson Laboratory has filed a complaint accusing Nanjing University of breeding and re-selling its mouse models, the Hartford Courant reports.

Oxford researchers are turning to virtual reality to visualize genes and regulatory elements, says.

In Science this week: neutrophils rely on microRNA to protect against lung inflammation, and more.

China is moving forward with plans to sequence a million citizens, the Wall Street Journal reports.